Mar 5, 2026 04:18PM
Mar 4, 2026 03:22PM
Mar 2, 2026 03:49PM
Mar 2, 2026 03:21PM
Mar 2, 2026 12:56PM
Mar 2, 2026 10:59AM
Mar 2, 2026 10:38AM Cantor Fitzgerald Reiterates Overweight Rating on Ascendis Pharma (ASND)
Mar 2, 2026 10:03AM
Mar 2, 2026 09:19AM
Mar 2, 2026 04:55AM
Feb 23, 2026 08:58AM
Feb 12, 2026 01:54PM
Feb 12, 2026 10:03AM
Feb 12, 2026 07:41AM BioMarin (BMRN), Ascendis (ASND) Trade Lower Following Competitor Data
Feb 11, 2026 04:01PM
Jan 22, 2026 11:56AM
Jan 20, 2026 05:30AM
Jan 12, 2026 08:26AM
Jan 12, 2026 08:18AM
Jan 9, 2026 07:10AM
Jan 8, 2026 04:04PM Ascendis reports positive 52-week trial data for achondroplasia treatment
Jan 8, 2026 08:49AM
Jan 7, 2026 09:13AM
Dec 12, 2025 03:22PM
Nov 26, 2025 07:00AM
Nov 26, 2025 06:48AM
Nov 24, 2025 08:53AM
Nov 17, 2025 04:10PM Wolfe Research Starts Ascendis Pharma (ASND) at Outperform
Nov 17, 2025 04:01PM
Nov 16, 2025 03:00PM
Nov 13, 2025 06:55AM
Nov 13, 2025 04:04AM
Nov 12, 2025 04:05PM
Nov 7, 2025 08:31AM
Oct 16, 2025 04:06PM Raymond James Starts Ascendis Pharma (ASND) at Strong Buy, PT $271, 'We see a high conviction path to a $4B+ top line'
Oct 13, 2025 07:21AM
Oct 12, 2025 03:00PM
Oct 8, 2025 04:01PM
Sep 24, 2025 06:00AM
Sep 23, 2025 08:59AM
Sep 8, 2025 09:46AM
Aug 20, 2025 08:25AM Ascendis Pharma (ASND) PT Raised to $260 at JPMorgan
Aug 8, 2025 10:13AM
Aug 8, 2025 08:40AM
Aug 8, 2025 08:16AM
Aug 8, 2025 05:42AM
Aug 8, 2025 05:29AM
Aug 8, 2025 05:23AM
Aug 7, 2025 04:04PM Ascendis Pharma (ASND) Tops Q2 EPS by 45c
Aug 4, 2025 07:09AM

341,965 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All